Gujarat Themis Biosyn Ltd · NSE:GUJTHEM
Gujarat Themis Biosyn — Q1 FY2023-24 Earnings Presentation
17 slides from Gujarat Themis Biosyn's earnings presentation, Aug 14, 2023
Slide 1: Investor Presentation cover letter to BSE
GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 REGD. OFFICE &FACTORY : 69/C GIDC INDUSTRIAL ESTATE, VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA TEL : 0260-2430027 / 2400639 E-mail:hrm@gtbl.in.net GTBL: CS: BSE-CORR/2023-24 14th August, 2023 To, BSE Limited, Floor 25, Phiroze Jeejeebhoy To
Slide 2: Result Update Presentation Q1 FY23-24
Gujarat Themis Biosyn Limited Result Update Presentation Q1 FY23-24
Slide 3: Disclaimer
Click to edit Master title style Disclaimer This presentation has been prepared by Gujarat Themis Biosyn Limited (the “Company” or “GTBL”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form t
Slide 4: Management Commentary
Click to edit MasterComment Management title style Commenting on the result, Dr. Sachin Patel, Director said : “The current quarter witnessed normalization of the tendering process leading to strong growth on sequential basis with the topline growing by 76% quarter-on-quarter. The demand for the cur
Slide 5: Highlights Q1 FY23-24 vs Q1 FY22-23
Click to edit Master Financial title–style Highlights Q1 FY23-24 vs Q1 FY22-23 10.33% 3.20% (328 bps) Revenue from Operations EBITDA EBITDA Margin Rs. 49.59 Crore Rs. 23.51 Crore 47.40% (0.27%) (380 bps) (0.25%) PAT PAT Margin Basic EPS Rs. 17.72 Crore 35.74% Rs. 12.20 vs. Rs 12.23 in Q1 FY2023 4
Slide 6: Quarterly Financial Highlights
Click to edit Master Quarterly titleHighlights Financial style Revenue (Rs. Cr) 47.7 49.6 44.9 28.8 28.2 28.2 Q4 FY21-22 Q1 FY22-23 Q2 FY22-23 Q3 FY22-23 Q4 FY22-23 Q1 FY23-24 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 25 50.7% 51.2% 53.0% 60% 45.5% 41.5% 47.4% 20 34.0% 39.5% 39.2% 45% 2
Slide 7: Q1 FY23-24 Financial Highlights
Click to Q1edit Master FY23-24 title style Financial Highlights Rs. Crs Q1 FY23-24 Q1 FY22-23 YoY% Q4 FY22-23 Income from Operations 49.59 44.94 28.17 Other Operating Income 0.00 0.00 0.00 Total Income from Operations 49.59 44.94 10.33% 28.17 Cost of Materials Consumed 6.41 7.67 6.96 Changes In Inve
Slide 8: Highlights FY22-23 vs FY21-22
Click to edit Master Financial title–style Highlights FY22-23 vs FY21-22 29.71% 27.86% (72 bps) Revenue from Operations EBITDA EBITDA Margin Rs. 148.97 Crore Rs. 74.22 Crore 49.82% 32.88% 93 bps 32.87% PAT PAT Margin Basic EPS Rs. 57.97 Crore 38.91% Rs. 39.90 vs. Rs 30.03 in FY2022 7
Slide 9: Annual Financial Highlights
Click to edit Master Annual Financialtitle style Highlights Revenue (Rs. Cr) 148.97 114.85 85.12 90.56 41.05 FY18-19 FY19-20 FY2021 FY21-22 FY22-23 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 80 49.8% 60% 50.5% 70 70 38.9% 45% 44.5% 50% 38.0% 60 37.4% 60 33.3% 40% 27.8% 35% 40% 50 58.0 50
Slide 10: Annual Financial Highlights FY22-23
Click to edit Master Annual Financialtitle style – FY22-23 Highlights Rs. Crs FY22-23 FY21-22 YoY% Income from Operations 148.97 114.85 Other Operating Income 0.00 0.00 Total Income from Operations 148.97 114.85 29.71% Cost of Materials Consumed 29.73 21.75 Changes In Inventory (3.24) (5.13) Employe
Slide 11: Balance Sheet Highlights as on 31st March 2023
Click to edit Master Balance title style– As on 31st March 2023 Sheet Highlights Rs. Cr. Rs. Cr. Mar 2023 Mar 2022 Mar 2023 Mar 2022 Total Equity & Liabilities Total Assets Shareholders Funds 149.15 103.32 Non Current Assets 105.48 44.11 Share Capital 7.26 7.26 32.21 18.22 Property Plant & Equipment
Slide 12: Key Balance Sheet Ratios
Click to Keyedit Master Balance title Sheet style Ratios RoCE(%)* RoA(%)** 37.0% 35.6% 34.9% 70.91% 34.2% 59.9% 57.9% 52.1% 19.6% 33.94% FY18-19 FY19-20 FY20-21 FY21-22 FY22-23 FY18-19 FY19-20 FY20-21 FY21-22 FY22-23 RoE(%)*** 56.1% 43.2% 42.2% 38.9% 34.6% FY18-19 FY19-20 FY20-21 FY21-22 FY22-23 ***
Slide 13: Fermentation based Intermediate manufacturer
Click Among to edit India’s Masterfew title style Fermentation based Intermediate manufacturer GTBL among one of India’s few fermentation-based manufacturers in pharmaceutical field State of Art Manufacturing Facility Incorporated in 1981 as joint Plant in Vapi (Gujarat) sector Company with GIIC
Slide 14: Product Portfolio – Growing at a fast pace
Click toStrong edit Master & Niche title style Product Portfolio – Growing at a fast pace Current Product Portfolio Rifamycin An intermediate for Rifamycin S An intermediate for manufacturing drug Rifampicin O manufacturing drug Rifaximin (Anti biotic used for treatment of (Antibiotic used for t
Slide 15: State of Art Manufacturing Facilities at Vapi
Click to editofMaster State title style Facilities at Vapi Art Manufacturing Among very few companies in India with fermentation capabilities for Intermediates Environment Friendly & Sustainable Process Using Aerobic Bacteria for Fermentation 14
Slide 16: Our Way Ahead
Click to Ouredit Way Master Aheadtitle style In process of identifying new products which have good domestic and export New Product Development & potential Company working on strategy to move up the value chain by way of forward Forward Integration integration into API New infrastructure being
Slide 17: Thank You
Click to editYou Thank Master title style For further information, please contact: Company : Investor Relations Advisors : Gujarat Themis Biosyn Limited Bridge Investor Relations Pvt. Ltd. Mr. Sangameshwar Iyer Ms. Savli Mangle - 9833361003 Mr. Rahul Trivedi - 9833541841 sangameshwar.iyer@themismedi
Gujarat Themis Biosyn — Q1 FY2023-24 Earnings Presentation on 6ix